[en] Although positron emission tomography (PET) imaging is now recognized as a useful tool for staging intermediate and high-grade non-Hodgkin's lymphoma (NHL), few data are available regarding its accuracy in low grade NHL. We therefore studied 36 patients with histologically proven low-grade NHL. Whole-body 2-(fluorine-18) fluoro-2-deoxy-D-glucose (FDG) PET was performed at the time of initial diagnosis (n = 21) or for disease recurrence (n = 15) prior to any treatment. PET results were compared to those of physical examination and computed tomography (CT). PET studies were read without knowledge of any clinical data. Any focus of increased activity was described and given a probability of malignancy using a 5 point-scale (0: normal to 4: definitively malignant). An individual biopsy was available for a total of 31 lesions. The sensitivity and specificity were 87% and 100% for FDG-PET, 100% and 100% for physical examination and 90% and 100% for CT respectively. In addition, 42 of 97 peripheral lymph node lesions observed by FDG-PET were clinically undetected, whereas the physical examination detected 23 additional nodal lesions. PET and CT both indicated 12 extranodal lymphomatous localizations. FDG-PET showed 7 additional extranodal lesions while 5 additional unconfirmed lesions were observed on CT. Regarding bone marrow infiltration, PET and biopsy were concordant in 24 patients with 11 true positive (TP) and 13 true negative (TN). However PET was FN in 11 patients and no biopsy was performed in one patient. The combination PET/CT/physical examination seems to be more sensitive than the conventional approach for staging low grade NHL. Its sensitivity however is unacceptably low for diagnosing bone marrow infiltration.
Disciplines :
Radiology, nuclear medicine & imaging Hematology
Author, co-author :
Najjar, F.
Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale
Rigo, Pierre ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire
Language :
English
Title :
Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin's Lymphomas (NHL)
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Som P., Atkims H.L., Bandophadhayah D. (1980) A fluorinated glucose analog, 2 f-fluoro-deoxy-glucose (F-18). J Nucl Med 21:670-675.
Warburg O. (1956) On the origin of cancer cells. Science 123:309-314.
Warburg O., Wind F., Neglers E. (1930) On the metabolism of tumors in the body. Metabolism of tumors , (Warburg O, ed). Constable, London; 254-270.
Rigo P., Paulus P., Kaschten B.J. (1996) Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23:1641-1674.
Conti P.S., Lilien D.L., Hawley K. (1996) PET and (18F)FDG in oncology: A clinical update. Nucl Med Biol 23:717-735.
Moog F., Bangerter M., Diederichs C.G. (1997) Lymphoma: Role of whole-body 2-deoxy-2-(F-18) fluoro-D-glucose positron emission tomography (FDG) PET in nodal staging. Radiology 302:795-800.
Hoh C.K., Glapsy J., Rosen P. (1997) Whole-body FDG-PET imaging for staging of Hodgkin's and lymphoma. J Nucl Med 38:343-348.
Bangerter M., Moog F., Buchmann I. (1998) Whole-body 2-deoxy-2-(F-18) fluoro-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9:1917-1922.
Jerusalem G., Warland V., Najjar F. (1999) Whole-body 18-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Com 20:13-20.
Najjar F., Jerusalem G., Paulus P. (1999) Whole-body FDG-PET for the evaluation of patients with aggressive non-Hodgkin's lymphoma. Méd Nucl Imag Fonc Mét 23:281-290.
Newman J.S., Francis I.R., Kamiski M.S., Wahl R.L. (1994) Imaging of lymphoma with PET with 2-(F-18)-fluoro-D-glucose: Correlation with CT. Radiology 190:111-116.
Rodriguez M., Rehn S., Ahlström H. (1995) Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 36:1790-1796.
Okada J., Yoshikawa K., Imazcki K. (1991) The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 32:686.
Castellino R.A., Blank N., Hoppe R.T. (1986) Hodgkin's disease: Contribution of chest CT in the initial staging evaluation. Radiology 27:603-605.
Stumpe K.D.M., Urbinelli M., Steinert H.C. (1998) Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 25:721-728.
Moog F., Bangerter M., Diederichs C.G. (1998) Extranodal malignant lymphoma: Detection with FDG-PET versus CT. Radiology 206:475-481.
Jerusalem G., Beguin Y., Fassotte M.F. (2000) Persistant tumor 18F-FDG uptake after few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85:613-618.
Jerusalem G., Beguin Y., Fassotte M.F. (1999) Positron emission tomography using 18-FDG for post-treatment evaluation of Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic values than classical CT-scan imaging. Blood 94:2429-2433.
Hoffmann M., Kletter K., Diemling M. (1999) Positron emission tomography using fluorine-18-fluoro-deoxy-D-glucose (F18-FDG) does not visualise extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 10:1185-1189.
Moog F., Bangerter M., Kotzerk J. (1998) 18-F-fluorodeoxyglucose positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603-609.
Bengel F.M., Ziegler S.I., Avril N. (1997) Whole-body positron emission tomography in clinical oncology: Comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 24:1091-1098.
Kotzerke J., Guhlmann A., Moog F. (1999) Role of attenuation correction for fluorine-18-fluorodeoxyglucose positron emission tomography in primary staging of malignant lymphoma. Eur J Nucl Med 26:31-38.
Hustinx R., Dolin R.J., Bénard F. (2000) Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: A free-response ROC analysis. Eur J Nucl Med 27:1365-1371.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.